Laying Out Lessons Learned from Early Development of ADCs
- Understanding why the dose of ADC matters
- Explaining how durability of response may be a better predictor of activity than ORR in early ADC trials
- How can we use predictive biomarkers to improve ADC patient selection; should we be looking beyond biomarkers of response to biomarkers of toxicity?